Literature DB >> 17884274

The amphetamine-induced sensitized state as a model of schizophrenia.

R E Featherstone1, S Kapur, P J Fletcher.   

Abstract

Schizophrenia is a serious psychiatric disorder which impacts a broad range of cognitive, behavioural and emotional domains. In animals, exposure to an intermittent, escalating dose regimen of amphetamine induces a sensitized state that appears to share a number of behavioural and neurochemical similarities with schizophrenia. In humans repeated exposure to amphetamine, or other psychomotor stimulants, can induce sensitization as well as psychosis. The following paper evaluates the evidence for the amphetamine-induced sensitized state as an animal model of schizophrenia, focussing separately on the positive, cognitive and negative symptoms associated with this disease. Current evidence supports the use of amphetamine sensitization as a model of the positive symptoms observed in schizophrenia. Additionally, there is increasing evidence for long-lasting cognitive deficits in sensitized animals, especially in the area of attention and/or cognitive flexibility. Other areas of cognition, such as long-term memory, appear to be unaltered in sensitized animals. Finally, little evidence currently exists to either support or refute the use of amphetamine sensitization as a model of negative symptoms. It is concluded that amphetamine sensitization likely impacts behaviour by altering the functioning of mesolimbic dopamine systems and prefrontal cortical function and can serve as a model of certain domains of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884274     DOI: 10.1016/j.pnpbp.2007.08.025

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  67 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 3.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

Review 4.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

5.  Extended access to methamphetamine self-administration affects sensorimotor gating in rats.

Authors:  Martin Hadamitzky; Athina Markou; Ronald Kuczenski
Journal:  Behav Brain Res       Date:  2010-11-09       Impact factor: 3.332

6.  Sensitization, drug addiction and psychopathology in animals and humans.

Authors:  Paul Vezina
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-28       Impact factor: 5.067

7.  Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.

Authors:  Masaki Tokunaga; Nicholas Seneca; Ryong-Moon Shin; Jun Maeda; Shigeru Obayashi; Takashi Okauchi; Yuji Nagai; Ming-Rong Zhang; Ryuji Nakao; Hiroshi Ito; Robert B Innis; Christer Halldin; Kazutoshi Suzuki; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 8.  Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction.

Authors:  Ruud van Winkel; Nicholas C Stefanis; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2008-08-20       Impact factor: 9.306

9.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

10.  Down-regulated GABAergic expression in the olfactory bulb layers of the mouse deficient in monoamine oxidase B and administered with amphetamine.

Authors:  Hsiang-Shu Yin; Kevin Chen; Jean C Shih; Tai-Wei Tien
Journal:  Cell Mol Neurobiol       Date:  2009-11-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.